Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.
Also called NCT03749057
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 400 participants
- Registry
-
NCT03749057
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03749057. Allocation not applicable; no masking; primary purpose treatment. Start 2018-11-20 (actual); primary completion 2025-03-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation
- Acronym
- ERSAF
- Condition
- Cerebral Infarction
- Condition
- TIA (transient ischemic attack)
- Intervention (Drug)
- Rivaroxaban
- Lead sponsor
- General Hospital of Shenyang Military Region
Record details
- Record id
cardio:ct-nct03749057- Content hash
9034bbf340dfa35740b49ac8e812c0a94ac9a798435c2744642918fad760f9f0